A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC is a phase 3 interventional study registered as NCT05884398 by Janssen Research & Development, LLC, with 420 participants enrolled, started 2023-08-31 and due to reach its primary completion in 2026-10-12. Interventions recorded: Apalutamide, Androgen-deprivation Therapy (ADT). Conditions listed: Metastatic Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Apalutamide, Johnson & Johnson, Prostate cancer.
- TrialA Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Shares Apalutamide, Johnson & Johnson, Prostate cancer.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Apalutamide, Johnson & Johnson, Prostate cancer.
- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide, Prostate cancer.
- TrialAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Shares Apalutamide, Johnson & Johnson, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide, Johnson & Johnson, Prostate cancer.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson, Prostate cancer.
- TrialStudy of Oral MRT-2359 With Apalutamide in Prostate Cancer
Shares Apalutamide, Prostate cancer.